What Happened

The FDA approved Ultragenyx's gene therapy Fayuvi for Sanfilippo syndrome type A, a rare inherited neurological disorder. This is the second FDA approval for an Ultragenyx gene therapy in a month, following Genglycos in August. The approval comes after a prior rejection in 2025 due to manufacturing issues, which have since been resolved.

Who Is Affected

Ultragenyx estimates 3,000 to 5,000 patients in commercially addressable markets. The therapy is indicated for children with preserved neurodevelopmental function, with an expected average age of treatment at 5 years old. The company will market Fayuvi through its existing salesforce, alongside other products like Genglycos.

Market Impact

• Therapy priced at $3.95 million wholesale, with first shipments in 30-60 days.
• Ultragenyx also announced upcoming 'significant expense reductions' following a Phase 3 failure of apazunersen, which may lead to vendor consolidation.
• The approval adds to Ultragenyx's growing product portfolio but does not avoid the planned cuts.

What to Watch

Monitor Ultragenyx's expense reduction details for potential vendor consolidation opportunities. The 30-60 day launch window is critical for vendors offering commercialization, manufacturing, or patient-support services. Also watch for newborn screening developments that could expand the addressable patient population.

Related coverage

• Sandoz CEO warns of Trump's generic drug tariff impact
• FDA approves eGenesis pig liver trial for acute liver failure treatment
• FDA approves Revolution Medicines' daraxonrasib for advanced pancreatic cancer
• FDA Accepts NDA for Apnimed's Sleep Apnea Pill AD109